Determining the incidence of familiality in ALS: A study of temporal trends in Ireland from 1994 to 2016
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Access
openAccess
Embargo end date
Citation
Ryan, M., Heverin, M., Doherty, M.A., Davis, N., Corr, E.M., Vajda, A., Pender, N., McLaughlin, R., Hardiman, O. Determining the incidence of familiality in ALS: A study of temporal trends in Ireland from 1994 to 2016, Neurology: Genetics, 2018, 4, 3, e239
Abstract
Objective: To assess temporal trends in familial amyotrophic lateral sclerosis (FALS) incidence rates in an Irish population and to determine factors influencing FALS ascertainment. Methods: Population-based data collected over 23 years, using the Irish amyotrophic lateral sclerosis (ALS) register and DNA biobank, were analyzed and age-standardized rates of FALS and associated familial neuropsychiatric endophenotypes were identified. Results: Between 1994 and 2016, 269 patients with a family history of ALS from 197 unique families were included on the register. Using stringent diagnostic criteria for FALS, the mean age-standardized FALS incidence rate for the study period was 11.1% (95% confidence interval[CI], 8.8–13.4). The FALS incidence rate increased steadily from 5.2% in 1994 to 19.1% in2016, an annual increase of 0.7% (95% CI, 0.5–0.9,p< 0.0001). Inclusion of the presence of neuropsychiatric endophenotypes within kindreds increased the FALS incidence rate to 30%. The incidence of FALS in newly diagnosed individuals from known families increased signif-icantly with time, accounting for 50% of all FALS diagnoses by 2016. The mean annual rate of recategorization from “sporadic ALS” to “FALS” was 3% (95% CI, 2.6–3.8). Conclusions: The true population-based rate of FALS is at least 20%. Inclusion of extended endophenotypes within kindreds increases the rate of FALS to 30%. Cross-sectional analysis of clinic-based cohorts and stringent definitions of FALS underestimate the true rate of familial disease. This has implications for genetic counseling and in the recognition of presymptomatic stages of ALS.
Description
Endorsement
Review
Supplemented By
Referenced By
Sponsor: Science Foundation Ireland (SFI)
Grant Number: 16/ERCD/3854
Sponsor: Science Foundation Ireland (SFI)
Grant Number: 15/SPP/3244
Author's Homepage: http://people.tcd.ie/hardimao
Type of material: Journal Article

